Cytyc Corp. said Monday that is will purchase Adeza Biomedical Corp. for $452 million.
Adeza has a product designed to identify women who are at risk for preterm birth, as well as a drug candidate to prevent preterm births. They have an estimated market of $500 million and $100 million, respectively.
Completion of the offer is anticipated by the end of March 2007.
Cytyc provides surgical and diagnostic products for women’s health and cancer diagnostics.
Adeza Biomedical manufactures and markets products for women’s health.
